| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5597466 | The Annals of Thoracic Surgery | 2017 | 7 Pages |
Abstract
The 2-year analysis of the observational European TRACE study suggests that managing HMII patients with a vitamin K antagonist with a target international normalized ratio of 2.3 without antiplatelet therapy may help to reduce the incidence of major bleeding without increasing the risk of thromboembolic events, including ischemic stroke and pump thrombosis.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ivan MD, PhD, Pierre-Yves MD, PhD, Michael MD, Erwan MD, Daniel MD, Laura RN, MPH, Kartik S. PhD, David J. PhD, Jan D. MD, EU TRACE Investigators EU TRACE Investigators,